Highest-materiality recent filing
Merck Q2 2026: GAAP loss $0.54 on $16.6B sales; raises FY2026 guidance
Total worldwide sales $16.6B, up 5% (4% ex-FX); KEYTRUDA/KEYTRUDA QLEX sales $8.4B (+5%).
Merck reports Q1 GAAP loss per share of $1.72 on $16.3B sales; narrows and raises full-year guidance
GAAP EPS loss of $1.72; Non-GAAP EPS loss of $1.28, both include $3.62/share charge for Cidara acquisition.
Merck Q4 Non-GAAP EPS $2.04 (+19% YoY); FY2026 guidance $5.00-$5.15 on Cidara charge
Q4 2025 sales $16.4B (+5% GAAP EPS $1.19, Non-GAAP EPS $2.04).
Merck closes $8.0B multi-tranche debt offering across eight series
Total $8.0B includes Floating Rate Notes due 2029 ($500M), 3.850% Notes due 2029 ($750M), 4.150% due 2031 ($1B), 4.450% due 2032 ($1B).
Merck Q3 GAAP EPS $2.32, non-GAAP $2.58; raises full-year non-GAAP EPS guidance to $8.93-8.98
Total sales $17.3B (+4% YoY, +3% ex-FX); GAAP net income $5.8B, non-GAAP $6.4B.
Merck reports Q2 2025 sales of $15.8B, down 2%, and announces $3B restructuring program
Total worldwide sales $15.8 billion, down 2% nominally and ex-forex vs Q2 2024; KEYTRUDA sales $8.0 billion, up 9%.
Merck reports Q1 2025 EPS $2.01, sales $15.5B; GARDASIL plunges 41% on China weakness
GAAP EPS $2.01 (up 7% YoY); non-GAAP EPS $2.22 (up 7%); revenue $15.5B (-2% reported, +1% ex-FX).
Merck Q4 2024 sales $15.6B (+7% YoY); GAAP EPS $1.48, Non-GAAP $1.72; FY2025 guidance issued
Full-year 2024 worldwide sales $64.2B (+7% YoY; +10% ex-FX).
Merck Q3 2024: GAAP EPS $1.24, Non-GAAP $1.57; Sales $16.7B (+4% YoY)
Total worldwide sales $16.7B, up 4% (7% ex-FX). GAAP EPS $1.24; Non-GAAP EPS $1.57.
Q2 revenue $16.1B (+7% YoY, +11% ex-FX); GAAP EPS $2.14, Non-GAAP EPS $2.28; KEYTRUDA sales $7.3B (+16%).
Merck subsidiary MSD Netherlands closes €3.4B offering of senior notes across four tranches
€850M each of 3.250% notes due 2032, 3.500% notes due 2037, 3.700% notes due 2044, 3.750% notes due 2054.
Merck Q1 sales up 9% to $15.8B; raises FY2024 sales and EPS guidance
GAAP EPS $1.87 (+68% YoY); Non-GAAP EPS $2.07 (+48% YoY). Sales $15.775B (+9%, +12% ex-FX).
Merck reports Q4 GAAP loss of $0.48/share; plans $4B restructuring; FY2024 EPS guidance $8.44-8.59
Q4 2023 GAAP net loss $1.2B ($0.48 loss per share); non-GAAP EPS $0.03, includes $1.69/share Daiichi Sankyo charge.
Merck Q3 revenue $16.0B (+7%), KEYTRUDA up 17%; cuts FY EPS guidance on $5.5B Daiichi Sankyo charge
Q3 total sales $16.0B (+7% YoY); GAAP EPS $1.86, Non-GAAP EPS $2.13 (+15% YoY).
Merck posts Q2 GAAP loss of $5.98B on $10.2B Prometheus charge; raises FY sales outlook
GAAP loss per share of $2.35 on net loss of $5,975M; includes $4.02/share charge for Prometheus acquisition.
Merck Q1 revenue $14.5B (-9%), GAAP EPS $1.11; raises FY non-GAAP EPS guidance to $6.88-$7.00
Q1 revenue $14.5B, down 9% YoY; excluding LAGEVRIO and FX, up 15%.
Merck Q4 GAAP EPS $1.18, revenue $13.8B; guides FY2023 non-GAAP EPS $6.80-$6.95
Q4 2022 GAAP EPS $1.18 (down 22% YoY); non-GAAP EPS $1.62 (down 10%); revenue $13.8B (+2%, +8% ex-FX).
Merck Q3 beats: rev $15B, non-GAAP EPS $1.85; raises FY outlook; Davis to become Chairman
Q3 revenue $15.0B (+14% YoY); GAAP EPS $1.28, non-GAAP EPS $1.85 (+4% from $1.78).
Merck Q2 revenue up 28% to $14.6B; non-GAAP EPS $1.87 vs $0.61; raises 2022 sales guidance
KEYTRUDA sales rose 26% to $5.3B; GARDASIL/GARDASIL 9 up 36% to $1.7B, driven by China demand.
Merck Q1 sales $15.9B (+50% YoY); Non-GAAP EPS $2.14; raises full-year guidance
Sales $15.9B, +50% YoY (52% ex-FX); KEYTRUDA $4.8B (+23%), LAGEVRIO contributed $3.2B.
Merck Q4 2021 revenue $13.5B (+24%), Non-GAAP EPS $1.80; FY2022 guidance issued
Q4 2021 sales $13.5B (+24% YoY); GAAP EPS $1.51, Non-GAAP EPS $1.80 (vs $0.98).
Merck Q3 sales $13.2B (+20% YoY); raises FY2021 guidance; to acquire Acceleron for $11.5B
Q3 GAAP EPS $1.80, Non-GAAP EPS $1.75; sales $13.2B (+20% YoY, +19% ex-FX).
Merck Q2 sales $11.4B (+22% YoY); raises full-year revenue guidance to $46.4B-$47.4B
GAAP EPS $0.48; non-GAAP EPS $1.31, up 28% YoY on strong demand recovery.
announcing the election of Surendralal L. “Lal” Karsanbhai to the Company’s Board of Directors (the “Board”), effective January 1, 2025.
On February 15, 2024, Peter C. Wendell gave notice to Merck & Co., Inc. (the “Company”) of his intention to retire from the Board of Directors of the Company (the “Board”) as of the Company’s 2024 Annual Meeting of Shareholders on May 28, 2024.
On November 21, 2023, Rita Karachun, Senior Vice President Finance – Global Controller and principal accounting officer of Merck & Co., Inc. (the “Company”), gave notice of her intention to resign from this position effective December 4, 2023.
On November 28, 2023, the Board of Directors (the “Board”) of the Company elected Dalton E. Smart III to serve as Senior Vice President Finance – Global Controller of the Company, effective December 4, 2023, making him the Company’s principal accounting officer.
Kenneth C. Frazier, the Executive Chairman of Merck’s Board of Directors (the “Board”) will retire from the Board, effective November 30, 2022.
the Board unanimously elected Robert M. Davis, Merck’s current Chief Executive Officer and President as well as a Director on the Board to serve as Chairman of the Board, effective December 1, 2022.
announcing the resignation of Leslie A. Brun from the Company’s Board of Directors effective August 19, 2021.
Max materiality 0.90 · Median 0.75 · Most common event earnings